Leadership changeRegulatory filing
What was reported
(b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026.U.S. Securities and Exchange Commission (EDGAR) · 8-K: CURRENT REPORT · Oct 14, 2026 · Open the source ↗
What the evidence supports
Longeveron told the SEC (Form 8-K, Item 5.02) that there was a change involving its directors or officers, or their pay arrangements. The filing gives Oct 7, 2026 as the date of the earliest event reported.
What remains unknown
The reasons for the change beyond those stated, and what it means for the company's strategy or results.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Form 8-K, Item 5.02 text(b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026.U.S. Securities and Exchange Commission (EDGAR) · 8-K: CURRENT REPORT · Oct 14, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:54 UTC
Longeveron reports changes involving its directors or officers (Form 8-K, Item 5.02)
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.